(Reference: Wilding et al., NEJM, 2021) Staying on GLP-1 medication is not forever is not necessary
Changes in plasma ( A ) AST, ( B ) ALT, and ( C ) C-reactive protein (CRP) levels
Patients sometimes ask whether splitting their weekly dose into two smaller injections might improve tolerability or effectivenessa question grounded in practical concerns about side effects and metabolic response
Human exploratory studies remain limited
These changes can improve insulin sensitivity, support weight loss, and reduce the risk of developing complications from diabetes or obesity
Whilst a direct causal link between retatrutide and joint pain has not been established, certain patient populations may be more predisposed to experiencing musculoskeletal symptoms during treatment whether related to the medication itself or to the physiological changes it induces